Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, December 1, 2022
[ Thu, Dec 01st 2022
] - WOPRAI
Wed, November 30, 2022
[ Wed, Nov 30th 2022
] - WOPRAI
[ Wed, Nov 30th 2022
] - WOPRAI
[ Wed, Nov 30th 2022
] - WOPRAI
[ Wed, Nov 30th 2022
] - WOPRAI
[ Wed, Nov 30th 2022
] - WOPRAI
[ Wed, Nov 30th 2022
] - WOPRAI
[ Wed, Nov 30th 2022
] - WOPRAI
[ Wed, Nov 30th 2022
] - WOPRAI
[ Wed, Nov 30th 2022
] - WOPRAI
[ Wed, Nov 30th 2022
] - WOPRAI
[ Wed, Nov 30th 2022
] - WOPRAI
[ Wed, Nov 30th 2022
] - WOPRAI
[ Wed, Nov 30th 2022
] - WOPRAI
[ Wed, Nov 30th 2022
] - WOPRAI
[ Wed, Nov 30th 2022
] - WOPRAI
[ Wed, Nov 30th 2022
] - WOPRAI
[ Wed, Nov 30th 2022
] - WOPRAI
[ Wed, Nov 30th 2022
] - WOPRAI
[ Wed, Nov 30th 2022
] - WOPRAI
[ Wed, Nov 30th 2022
] - WOPRAI
[ Wed, Nov 30th 2022
] - WOPRAI
[ Wed, Nov 30th 2022
] - WOPRAI
[ Wed, Nov 30th 2022
] - WOPRAI
[ Wed, Nov 30th 2022
] - WOPRAI
[ Wed, Nov 30th 2022
] - WOPRAI
[ Wed, Nov 30th 2022
] - WOPRAI
[ Wed, Nov 30th 2022
] - WOPRAI
Mayank Mamtani Maintained (ARWR) at Strong Buy with Decreased Target to $59 on, Nov 30th, 2022
Mayank Mamtani of B. Riley Securities, Maintained "Arrowhead Pharmaceuticals, Inc." (ARWR) at Strong Buy with Decreased Target from $65 to $59 on, Nov 30th, 2022.
Mayank has made no other calls on ARWR in the last 4 months.
There are 5 other peers that have a rating on ARWR. Out of the 5 peers that are also analyzing ARWR, 2 agree with Mayank's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Andrew Galler of "Morgan Stanley" Maintained at Hold with Decreased Target to $37 on, Tuesday, November 29th, 2022
- Mani Foroohar of "SVB Leerink" Maintained at Hold with Decreased Target to $31 on, Tuesday, November 29th, 2022
These are the ratings of the 3 analyists that currently disagree with Mayank
- Maury Raycroft of "Jefferies" Maintained at Strong Buy with Decreased Target to $75 on, Tuesday, November 29th, 2022
- Edward Tenthoff of "Piper Sandler" Maintained at Buy with Decreased Target to $64 on, Thursday, November 10th, 2022
- Madhu Kumar of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $65 on, Monday, August 8th, 2022
